Theraclone Sciences, a US-based developer of antibodies (pictured) for targeting cancer formerly known as Spaltudaq, has signed a research collaboration with US-listed drugs company Pfizer worth up to $632m.
Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration. Theraclone is eligible for undisclosed royalties and up to $632 in research funding and milestone payments.
Theraclone raised $29m in its series B round in March 2007 from Amgen Ventures, the corporate venturing unit of Amgen, and venture capital and debt firms Alexandria Real Estate Equities, Arch Venture Partners, Canaan Partners, HealthCare Ventures, MPM Capital and Versant Ventures, after incubation by Accelerator and initial backing by a consortium including OVP Venture Partners and Versant Ventures.